In a previous Phase 1 clinical study, we assessed a sequential combination therapy with ropeginterferon alfa-2b (ropeg), a novel polyethylene glycol-conjugated recombinant proline-IFN-α [55,56], and nivolumab in patients with hepatitis B-related HCC who had undergone surgical tumor removal [57]. Here, IFNA1 is linked to hepatocellular carcinoma.